Inhibitors of endothelin.
With the advent of the first generation of both selective and nonselective endothelin antagonists being a relatively recent event, the manifold therapeutic potentials of these compounds are only now being explored clinically. Undoubtedly, numerous clinical utilities for these compounds will soon be realized.
Webb
M L
ML
Department of Cardiovascular Biochemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-400, USA.
Meek
T D
TD
D002318:Cardiovascular Diseases / Q000188:drug therapy; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000037:antagonists & inhibitors* / Q000145:classification / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D008967:Molecular Biology; D017466:Receptors, Endothelin / Q000145:classification / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D014018:Tissue Distribution
D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D017466:Receptors, Endothelin